webinar register page

Topic

A Conversation with Neurogene's Leadership

Description

Last month the biopharmaceutical company Neurogene announced that they are pursuing a Rett syndrome gene replacement program.

Rachel McMinn, PhD, who serves as CEO, founded Neurogene in 2018, inspired by her experience with her brother, who lives with an undiagnosed neurological disease. That same year RSRT introduced Dr. McMinn to Stuart Cobb, PhD, who soon became the company’s Chief Scientific Officer.

RSRT has collaborated with both Neurogene and the University of Edinburgh for a number of years. Over the past decade, RSRT has provided almost $3 million to the University of Edinburgh to support Dr. Cobb’s research on gene replacement and RNA modification approaches to cure Rett syndrome.

Dr. McMinn and Dr. Cobb will join RSRT's CEO, Monica Coenraads, for a conversation with the Rett community. We hope you will join us to learn more about Neurogene’s program for Rett syndrome.

Time

Jul 1, 2022 12:00 PM in Eastern Time (US and Canada)

Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: .

All fields are required

Your Information
Send to
Message preview	Hi there, You are invited to a Zoom webinar. When: Jul 1, 2022 12:00 PM Eastern Time (US and Canada) Topic: A Conversation with Neurogene's Leadership Register in advance for this webinar: https://us02web.zoom.us/webinar/register/WN_rqoq7_1IREijdnO_R41w5g After registering, you will receive a confirmation email containing information about joining the webinar. ---------- Webinar Speakers Rachel McMinn, PhD (Founder & CEO @Neurogene) Dr. McMinn founded Neurogene in January 2018 with the mission of providing genetic medicines to improve the lives of neurologically impaired and developmentally delayed children and their families. Dr. McMinn currently serves as CEO of Neurogene. Prior to this, she spent 17 years in the biotechnology industry, most recently serving as the Chief Business and Strategy Officer of Intercept Pharmaceuticals, a company dedicated to patients with serious liver disease. Dr. McMinn was also an award-winning biotechnology analyst, with 13 years of experience at firms including Bank of America Merrill Lynch, Cowen, and Piper Jaffray. She earned her doctorate from The Scripps Research Institute and was awarded a Post-Doctoral Miller Fellowship at the University of California, Berkeley. Stuart Cobb, PhD (Chief Scientific Officer @Neurogene) Dr. Cobb leads Neurogene’s scientific research, developing its scientific strategy to support its existing and growing gene therapy portfolio, as well as identifying novel technologies that complement its pipeline. In addition to his work at Neurogene, Dr. Cobb also leads a research team at the University of Edinburgh, where he is a Simons Fellow and Reader in Neuroscience at the Patrick Wild Centre and Centre for Discovery Brain Sciences. Dr. Cobb's research has focused on developing novel genetic treatments for brain disorders based on a deep understanding of the molecular and cellular pathology. Dr. Cobb’s work has been published in leading journals and includes seminal work on the inherent reversibility of neurological features in neurodevelopmental disease. Dr. Cobb has a B.Sc. from the University of Glasgow and a Ph.D. in neuroscience from the University of Oxford, UK. Monica Coenraads (moderator) (CEO @Rett Syndrome Research Trust) Monica Coenraads’s involvement with Rett syndrome began the day her then-two-year-old daughter was diagnosed with the disorder. A year later, in 1999, she co-founded the Rett Syndrome Research Foundation (RSRF) and held the position of scientific director during the eight years of the Foundation’s drive to stimulate scientific interest and research in Rett syndrome, culminating with the groundbreaking work in 2007 which demonstrated the first global reversal of symptoms in preclinical models of the disorder. Monica launched the Rett Syndrome Research Trust in late 2008 to pursue the next steps from that milestone. As chief executive officer she oversees all aspects of the organization, including day-to-day operations, strategic direction, fundraising, and communications. Together with her colleagues and with input from advisors and the scientific community at large, Monica sets and executes RSRT's research agenda.

Time Zone:

webinar register page

Share via Email

Switch Time Zone

Upcoming Meetings